Insmed Announces Pricing of Public Offering of Convertible Senior Notes
January 23, 2018 22:49 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it priced its registered underwritten public offering of $400 million aggregate principal...
Insmed Announces Proposed Public Offering of Convertible Senior Notes
January 22, 2018 16:01 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it has commenced an underwritten public offering of $300 million aggregate principal...
Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial Preparations
January 03, 2018 16:10 ET
|
Insmed, Inc.
Interim results from INS-312 show that 28% of patients who previously received 6 months of guideline based therapy (GBT) alone achieved culture conversion following addition of ALIS to therapy,...
Insmed to Present at the Nasdaq 37th Annual Investor Conference
November 28, 2017 08:00 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 22, 2017 16:30 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed to Present at Two November Conferences
November 08, 2017 16:30 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update
November 02, 2017 07:30 ET
|
Insmed, Inc.
During the third quarter, the Company announced positive top-line results from its Phase 3 CONVERT Study of ALIS (amikacin liposome inhalation suspension) in patients with NTM lung disease caused by...
Insmed to Host Third Quarter 2017 Financial Results Conference Call on Thursday, November 2, 2017
October 25, 2017 08:00 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed to Present at Two September Investor Conferences
September 19, 2017 08:00 ET
|
Insmed Incorporated
BRIDGEWATER, N.J., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed Announces Closing of Public Offering
September 11, 2017 16:01 ET
|
Insmed Incorporated
BRIDGEWATER, N.J., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced the closing today of its previously announced public offering of its common stock. Insmed issued...